Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Harrington, KJ; Ferris, RL; Blumenschein, G; Colevas, AD; Fayette, J; Licitra, L; Kasper, S; Even, C; Vokes, EE; Worden, F; Saba, NF; Kiyota, N; Haddad, R; Tahara, M; Grunwald, V; Shaw, JW; Monga, M; Lynch, M; Taylor, F; DeRosa, M; Morrissey, L; Cock

Harrington, KJ (reprint author), Royal Marsden Hosp, Natl Inst Hlth Res Biomed Res Ctr, Inst Canc Res, London SW3 6JB, England.

LANCET ONCOLOGY, 2017; 18 (8): 1104

Abstract

Background Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索